Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.

Manuela Giachelia; Francesco D'Alo'; Stefan Hohaus; Maria Teresa Voso; Giuseppe Leone

doi:10.1016/j.leukres.2010.07.022

Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.

Manuela Giachelia, Francesco D'Alo', Stefan Hohaus, Maria Teresa Voso, Giuseppe Leone

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells

Original language	English
Pages (from-to)	465-471
Number of pages	7
Journal	Leukemia Research
Volume	35
DOIs	https://doi.org/10.1016/j.leukres.2010.07.022
Publication status	Published - 2011

Keywords

Hematopoietic stem cells
Myelodysplastic syndrome
decitabine
gene expression

Access to Document

10.1016/j.leukres.2010.07.022

Cite this

@article{5ef824b8f6b3482094d44b1c7a02e1e2,

title = "Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.",

abstract = "Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells",

keywords = "Hematopoietic stem cells, Myelodysplastic syndrome, decitabine, gene expression, Hematopoietic stem cells, Myelodysplastic syndrome, decitabine, gene expression",

author = "Manuela Giachelia and Francesco D'Alo' and Stefan Hohaus and Voso, {Maria Teresa} and Giuseppe Leone",

year = "2011",

doi = "10.1016/j.leukres.2010.07.022",

language = "English",

volume = "35",

pages = "465--471",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Oxford,United Kingdom: Elsevier Science Limited -Oxford : Pergamon, 1977-",

}

TY - JOUR

T1 - Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.

AU - Giachelia, Manuela

AU - D'Alo', Francesco

AU - Hohaus, Stefan

AU - Voso, Maria Teresa

AU - Leone, Giuseppe

PY - 2011

Y1 - 2011

N2 - Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells

AB - Abnormal gene promoter methylation contributes to deregulate gene expression of hematopoietic progenitors in myelodysplastic syndromes (MDS). We analyzed the gene expression profile of myelodysplastic and normal CD34+ hematopoietic stem cells (HSCs) treated in vitro with decitabine. We identified a list of candidate tumor suppressor genes, expressed at low levels in MDS HSCs and induced by hypomethylating treatment only in MDS, but not in normal HSCs. Real-time RT-PCR confirmed reduced CD9 expression in MDS CD34+ and bone marrow mononuclear cells, compared to normal controls. CD9 was specifically up-regulated by decitabine treatment in myelodysplastic CD34+ cells

KW - Hematopoietic stem cells

KW - Myelodysplastic syndrome

KW - decitabine

KW - gene expression

KW - Hematopoietic stem cells

KW - Myelodysplastic syndrome

KW - decitabine

KW - gene expression

UR - http://hdl.handle.net/10807/6312

U2 - 10.1016/j.leukres.2010.07.022

DO - 10.1016/j.leukres.2010.07.022

M3 - Article

SN - 0145-2126

VL - 35

SP - 465

EP - 471

JO - Leukemia Research

JF - Leukemia Research

ER -

Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this